Xenon Pharmaceuticals Inc. $XENE Shares Acquired by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB raised its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 71.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 139,000 shares of the biopharmaceutical company’s stock after acquiring an additional 58,000 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Xenon Pharmaceuticals were worth $6,230,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Wellington Management Group LLP increased its position in shares of Xenon Pharmaceuticals by 66.0% during the third quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock valued at $144,936,000 after acquiring an additional 1,435,096 shares during the last quarter. Capital International Investors increased its position in shares of Xenon Pharmaceuticals by 7.3% during the fourth quarter. Capital International Investors now owns 3,414,959 shares of the biopharmaceutical company’s stock valued at $153,058,000 after acquiring an additional 233,466 shares during the last quarter. Commodore Capital LP increased its position in shares of Xenon Pharmaceuticals by 30.1% during the second quarter. Commodore Capital LP now owns 3,025,000 shares of the biopharmaceutical company’s stock valued at $94,682,000 after acquiring an additional 700,000 shares during the last quarter. Vestal Point Capital LP increased its position in shares of Xenon Pharmaceuticals by 53.8% during the second quarter. Vestal Point Capital LP now owns 2,000,000 shares of the biopharmaceutical company’s stock valued at $62,600,000 after acquiring an additional 700,000 shares during the last quarter. Finally, Holocene Advisors LP increased its position in shares of Xenon Pharmaceuticals by 9.2% during the third quarter. Holocene Advisors LP now owns 1,976,553 shares of the biopharmaceutical company’s stock valued at $79,359,000 after acquiring an additional 167,078 shares during the last quarter. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Gary Patou sold 1,322 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $70,251.08. Following the completion of the sale, the director owned 24,896 shares in the company, valued at approximately $1,322,973.44. The trade was a 5.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gillian Cannon sold 1,190 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $63,236.60. Following the sale, the director owned 1,455 shares of the company’s stock, valued at $77,318.70. This represents a 44.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 4.07% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

XENE has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Xenon Pharmaceuticals from $56.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, March 10th. JPMorgan Chase & Co. lifted their price objective on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “overweight” rating in a report on Wednesday, May 27th. Wedbush dropped their price objective on shares of Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating for the company in a report on Monday, March 16th. Bank of America restated a “buy” rating on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Finally, Wolfe Research initiated coverage on shares of Xenon Pharmaceuticals in a report on Monday, February 23rd. They issued an “outperform” rating and a $60.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Xenon Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $77.20.

Xenon Pharmaceuticals Stock Down 0.2%

Shares of Xenon Pharmaceuticals stock opened at $52.10 on Friday. Xenon Pharmaceuticals Inc. has a 52-week low of $30.00 and a 52-week high of $63.95. The company has a 50 day moving average of $55.41 and a 200 day moving average of $48.95. The company has a market capitalization of $5.04 billion, a P/E ratio of -11.09 and a beta of 0.62.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($1.17). During the same quarter in the previous year, the company posted ($0.83) earnings per share. As a group, research analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current fiscal year.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical?stage biopharmaceutical company dedicated to discovering and developing novel, small?molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion?channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion?channel biology and structure?based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.